Porkholm M, Toiviainen-Salo S, Seuri R, Lönnqvist T, Vepsäläinen K, Saarinen-Pihkala UM, Pentikäinen V, Kivivuori SM from the Division of Hematology-Oncology and Stem Cell Transplantation, the Division of Child Neurology, the Division of Pediatrics and the Department of Pediatric Radiology from the University of Helsinki and Helsinki University Hospital, Helsinki, Finland. have just published an article entitled "Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential." in Acta Paediatrica.
They report on 17 children with refractory or high-risk malignancies who were treated with a maintenance therapy that consisted of metronomic thalidomide, etoposide and celecoxib. The endpoints of the study were overall and progression-free survival, changes in the Karnofsky-Lansky scores from baseline to the end of the study therapy and radiological responses. The median overall survival after the start of the study therapy was 6.2 months (range 2.0-57.7) and the six, 12 and 24-month survival rates were 59%, 18% and 18%, respectively. The median progression-free survival was 3.2 months (range 0.3-17.8). The Karnofsky-Lansky scores increased significantly during the study therapy (p=0.02), with 35% of the patients having a transient improvement in their clinical status. Radiologically, one partial response and two disease stabilisations were encountered. Grade III-IV adverse events occurred in 76% of the patients. This report highlight that metronomics can increase the quality of life during palliative care for childhood cancer, but requires careful patient selection to minimise the risk of serious adverse events.
You can access the full text on the website of the journal here